scholarly journals Conservative Management of Presumed Fetal Anemia Secondary to Maternal Chemotherapy for Acute Myeloid Leukemia

2021 ◽  
Vol 11 (04) ◽  
pp. e137-e141
Author(s):  
Christina M. Nowik ◽  
Alina S. Gerrie ◽  
Jonathan Wong
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Peak Systolic Velocity ◽  
Expectant Management ◽  
Fetal Monitoring ◽  
First Trimester ◽  
Term Treatment ◽  
Fetal Anemia ◽  
First Case ◽  
Acute Myeloid

Acute myeloid leukemia occurs rarely during pregnancy. When it is diagnosed remote from term, treatment in the form of daunorubicin plus cytarabine induction with consolidative cytarabine is typically undertaken after the first trimester. There is little data to guide fetal monitoring, in particular, whether and how often middle cerebral artery peak systolic velocity (MCA PSV) should be measured to screen for fetal anemia. Cytarabine may be particularly myelosuppressive to the fetus, but information pertaining to the management of this complication is also lacking in published literature. To our knowledge, we present the first case of presumed severe fetal anemia related to in utero exposure to chemotherapy that was managed conservatively with close sonographic monitoring, including serial measurement of MCA PSV. This case suggests that in the absence of hydrops fetalis or other signs of fetal decompensation, expectant management with ultrasound twice weekly, including MCA PSV, is appropriate. Ultrasounds may be decreased to weekly when MCA PSV does not suggest fetal anemia. Screening for fetal anemia can provide helpful information to guide the timing of chemotherapy administration and delivery. Key Points

scholarly journals Saprochaete clavata Infection in Immunosuppressed Patients: Systematic Review of Cases and Report of the First Oral Manifestation, Focusing on Differential Diagnosis

2021 ◽  
Vol 18 (5) ◽  
pp. 2385
Author(s):  
Carlo Lajolo ◽  
Rupe Cosimo ◽  
Schiavelli Anna ◽  
Gioco Gioele ◽  
Metafuni Elisabetta ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Acute Myeloid Leukemia ◽  
Differential Diagnosis ◽  
Myeloid Leukemia ◽  
Oral Manifestation ◽  
First Case ◽  
Immunosuppressed Patients ◽  
Meta Analyses ◽  
Acute Myeloid

Background: Saprochaete clavata infection is an emerging issue in immunosuppressed patients, causing fulminant fungaemia. The purpose of this systematic review of cases is to retrieve all cases of S. clavata infection and describe oral lesions as the first manifestation of S. clavata infection. Methods: We report the first case of intraoral S. clavata infection in Acute Myeloid Leukemia (AML) affected subject, presenting as multiple grayish rapidly growing ulcerated swellings, and provide a review of all published cases of infection caused by S. clavata, according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, conducted by searching SCOPUS, Medline, and CENTRAL databases. Only articles in English were considered. Individual patient data were analyzed to identify risk factors for S. clavata infection. Results: Seventeen of 68 retrieved articles were included in the review reporting data on 96 patients (mean age 51.8 years, 57 males and 38 females). Most cases were disseminated (86) with a 60.2% mortality rate. Ninety-five were hematological patients, with AML being the most common (57 cases). Conclusions:S. clavata infection in immunosuppressed patients has a poor prognosis: middle-age patients, male gender and Acute Myeloid Leukemia should be considered risk factors. In immunosuppressed patients, the clinical presentation can be particularly unusual, imposing difficult differential diagnosis, as in the reported case.

Apiotrichum veenhuisii isolated from a pediatric patient with acute myeloid leukemia: The first case in humans

Mycologia ◽  
2019 ◽  
Vol 111 (5) ◽  
pp. 793-797
Author(s):  
Bruna Rossini Lara ◽  
Milena Barrocali de Araújo Melo ◽  
Claudete Rodrigues Paula ◽  
Mariana Volpe Arnoni ◽  
Cirilo Cesar Naozuka Simões ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Pediatric Patient ◽  
Myeloid Leukemia ◽  
First Case ◽  
Acute Myeloid

CD19 Expression in t(8;21)-Negative Acute Myeloid Leukemia Is Not Restricted to Cytogenetically Aberrant Populations.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4128-4128
Author(s):  
Jawad Francis ◽  
Avinash Dharmadhikari ◽  
Sheila N.J. Sait ◽  
George Deeb ◽  
Paul K. Wallace ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Normal Karyotype ◽  
Leukemic Cells ◽  
Aberrant Expression ◽  
The Third ◽  
Signal Pattern ◽  
First Case ◽  
Cd19 Expression ◽  
Acute Myeloid

Abstract Abstract 4128 Aberrant expression of the B lymphoid marker, CD19, in acute myeloid leukemia (AML) has frequently been associated with t(8;21)(q22;q22). However, AML cases lacking this translocation may occasionally express CD19. We identified eight such cases at Roswell Park Cancer Institute. Three of these cases had noticeable CD19-positive leukemic subsets with the following karyotypic abnormalities. The first case had monosomy X in 6 cells and normal karyotype in 14, the second case had trisomy 22 in 19 cells and normal karyotype in one, and the third case had monosomy 7 in 18 cells and trisomy 18 in two. We therefore asked if CD19 expression is restricted to the karyotypically abnormal leukemic cells. Bone marrow cells were sorted according to the specific immunophenotype. First, a generous mononuclear sorting region was drawn in the bivariate display of forward versus side scatter to exclude debris and aggregates. Next, the CD45-negative to CD45-dim, CD19-positive and CD34-positive leukemic cells were sorted. Fluorescent in situ hybridization (FISH) studies were carried out on the sorted samples using the following commercially available probes: the Centromere enumeration probe CEP X (SpectrumGreen) in the first case; the locus specific BCR (22q11) (SpectrumGreen)/ABL1 (9q34) (SpectrumOrange) dual color, dual fusion, translocation probe in the second, and the locus specific D7S486 (7q31) SpectrumOrange/CEP 7 SpectrumGreen probe in the third. A total of 200 nuclei were assessed in each case. The results are displayed in the Table below. There were no significant differences in the signal pattern between the CD19-positive and CD19-negative leukemic populations. These results indicate that aberrant CD19 expression in t(8;21)-negative AML is not restricted to leukemic cells that harbor specific karyotypic abnormalities. Table FISH results based on CD19 expression Case # Probe Signal Pattern CD19-positive CD19-negative 1 CEP X 1 Green (-X) 20/200 30/200 2 BCR/ABL 3 Green/2 Orange (+22) 163/200 170/200 3 CEP 7 1 Green/1 Orange (-7) 200/200 200/200 Disclosures: No relevant conflicts of interest to declare.

scholarly journals Spontaneous Complete Remission in a Patient with Acute Myeloid Leukemia and Severe Sepsis

2017 ◽  
Vol 2017 ◽  
pp. 1-3
Author(s):  
Rambod Mozafari ◽  
Mahsa Moeinian ◽  
Ali Asadollahi-Amin
Keyword(s):  
Acute Myeloid Leukemia ◽  
Severe Sepsis ◽  
Complete Remission ◽  
Short Duration ◽  
Myeloid Leukemia ◽  
Spontaneous Remission ◽  
Blood Transfusions ◽  
First Case ◽  
Long Duration ◽  
Acute Myeloid

Without treatment, acute myeloid leukemia (AML) is almost always fatal. Spontaneous remission of AML is a rare phenomenon and usually with a short duration. The exact mechanisms are unknown. However, its association with infection and blood transfusions has been described. We report a 53-year-old male who presented with severe sepsis and who was diagnosed with AML (M4). He has experienced complete spontaneous remission with relatively long duration. To the best of our knowledge, it is the first case of spontaneous remission described in Iran.

scholarly journals Myelodysplasia-related acute myeloid leukemia and acute promyelocytic leukemia: concomitant occurrence of two molecularly distinct diseases

2018 ◽  
Vol 10 (3) ◽  
Author(s):  
Yenny Alejandra Moreno Vanegas ◽  
Abdel-Ghani M. Azzouqa ◽  
David M. Menke ◽  
James M. Foran ◽  
Prakash Vishnu
Keyword(s):  
Acute Myeloid Leukemia ◽  
Acute Promyelocytic Leukemia ◽  
Myeloid Leukemia ◽  
Promyelocytic Leukemia ◽  
Simultaneous Occurrence ◽  
All Trans Retinoic Acid ◽  
First Case ◽  
Night Sweats ◽  
Radiotherapy Treatment ◽  
Acute Myeloid

Concurrent presentation of acute promyelocytic leukemia (APL) with other hematologic diseases in the absence of previous chemotherapy or ionizing radiotherapy treatment is very rare. We present a case of simultaneous occurrence of APL with myelodysplastic syndrome (MDS)-related acute myeloid leukemia (AML). A 43-yearold female presented with 3 month of history fatigue, night sweats, chills and pancytopenia. Bone marrow aspirate and biopsy demonstrated 20% myeloid blasts with dysplastic changes admixed with abnormal promyelocytes. Cytogenetic analysis showed tetraploidy and deletion in chromosomes 5q and 7q and polymerase chain reaction showed presence of PML/RARA mRNA transcripts, confirming the presence of concurrent APL and MDS-related AML. Induction chemotherapy with cytarabine and daunorubicin was initiated along with all-trans retinoic acid. This is the first case to be reported in the literature of concurrent occurrence of APL with MDS-related AML. Treatment with 7 + 3 regimen and ATRA was successful in inducing complete remission.

scholarly journals Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia

2017 ◽  
Vol 2017 ◽  
pp. 1-4
Author(s):  
Abhishek Mangaonkar ◽  
Hassan Al Khateeb ◽  
Narjust Duma ◽  
Erik K. St. Louis ◽  
Andrew McKeon ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Myeloid Leukemia ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
First Case ◽  
Immune Mediated ◽  
Related Donor ◽  
Work Up ◽  
Acute Myeloid

Background/Aims. Autonomic dysfunction (AD) after allogeneic stem cell transplant (SCT) is a rare occurrence and likely immune-mediated in etiology. There is limited literature on this topic and hence, we wish to briefly describe management of two cases at our institution and their outcomes. Methods. We retrospectively identified two patients with immune-mediated AD after SCT from our database. Immune-mediated AD was defined as AD secondary to an immune-mediated etiology without an alternative cause and responding to immunosuppression. Results. The first case is of a 32-year-old man with acute myeloid leukemia (AML) who underwent double umbilical cord allogeneic SCT. The second patient was a 51-year-old woman with secondary AML who underwent matched-related donor allogeneic SCT. Both underwent an extensive work-up for an underlying etiology prior to treatment with intravenous immunoglobulin (IVIG). Conclusions. AD after SCT is a rare yet significant clinical entity. A work-up of underlying etiology should be performed. IVIG is a treatment option for these patients.

scholarly journals Undetected Severe Fetal Myelosuppression following Administration of High-Dose Cytarabine for Acute Myeloid Leukemia: Is More Frequent Surveillance Necessary?

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Jessica Parrott ◽  
Marium Holland
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
High Dose ◽  
Fetal Anemia ◽  
Blood Cell Count ◽  
Normal Platelet ◽  
High Dose Cytarabine ◽  
Initial Ph ◽  
Acute Myeloid ◽  
Count Recovery

Background. Cytarabine use during pregnancy carries a 5–7% risk of neonatal cytopenia. We report two cases of fetal myelosuppression following high-dose cytarabine administration for acute myeloid leukemia (AML). Case 1. A 36-year-old G9P6 diagnosed with AML at 21 weeks was monitored for fetal anemia weekly and growth monthly. At 33 weeks (after 2 cycles), BPP was 2/10 and MCA PSV was elevated at 1.51 MoM. Urgent cesarean section was performed. The infant had an initial pH of 6.78 and pancytopenia (hematocrit 13.3%, platelets 3 K/UL, and white blood cell count 2.0 K/UL). Initially transfusion dependent, the neonate had count recovery by 3 weeks. Case 2. A 30-year-old G4P3 with AML at 26 weeks was monitored for fetal anemia twice weekly and growth monthly. At 34 weeks (after cycle 1), she was admitted with neutropenic fever. The fetal MCA PSV was borderline at 1.48 MoM. It improved to 1.38 MoM at 35 weeks but the fetal tracing worsened. At delivery the fetus was found to have a hematocrit of 30%, but with normal platelet and WBC. The fetus did not require any transfusions. Conclusion. Cytarabine use during pregnancy may cause neonatal myelosuppression. We recommend monitoring for fetal anemia with MCA Dopplers twice weekly.

scholarly journals First case of breakthrough pneumonia due toAspergillus nomiusin a patient with acute myeloid leukemia

2012 ◽  
Vol 50 (7) ◽  
pp. 746-750 ◽  
Author(s):  
Morena Caira ◽  
Brunella Posteraro ◽  
Maurizio Sanguinetti ◽  
Elena de Carolis ◽  
Giuseppe Leone ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
First Case ◽  
Acute Myeloid

scholarly journals Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Sakshi Jasra ◽  
Mohammed Kazemi ◽  
Nishi Shah ◽  
Jiahao Chen ◽  
Karen Fehn ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Case Report ◽  
Combination Therapy ◽  
Elderly Patients ◽  
Myeloid Leukemia ◽  
Complete Response ◽  
First Case ◽  
Fda Approval ◽  
Acute Myeloid ◽  
Refractory Aml

AbstractOptimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractory AML, achieving complete response to the combination therapy of hypomethylating agent, Azacytidine with the IDH2 inhibitor, Enasidenib, and BCL2 inhibitor, Venetoclax. To our knowledge, this is the first case report of a patient with IDH2 mutated refractory AML achieving complete response to combination therapy with azacytidine, enasidenib and venetoclax.

Sign in / Sign up

Export Citation Format

Share Document